Short answer
Alamar Biosciences Inc (ALMR) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $34M with net income of −$13M.
Q3 2026 key financials · XBRL
- Revenue
- $34M
- +14.0% QoQ
- Net income
- −$13M
- −1.1% QoQ
- Operating margin
- -45.1%
- Gross margin
- 61.5%
- EPS (diluted)
- −$0.05
- −106.5% QoQ
Source: XBRL data from the Alamar Biosciences Inc (ALMR) Q3 2026 10-Q on SEC EDGAR. USD.
Alamar Biosciences Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $33.5M, up $13.6M YoY, driven by product revenue growth to $26.3M
- Consumables best performer: $17.8M, up 79% YoY, versus instruments $8.5M, up 50%
- Gross margin 61.5% vs 59.7% YoY, while net loss widened to $13.3M from $8.0M
- Cash, equivalents and short-term investments $226.6M, with operating cash outflow of $46.4M for nine months
- Outlook: continued operating losses, higher R&D and SG&A, full-year 2026 stock compensation of $13M to $15M
Risk Factors
- AI regulation risk: EU AI Act compliance may impose fines up to €35 million or 7% of worldwide annual turnover
- FDA compliance risk: QMSR replaced QSR in February 2026, potentially increasing medical-device compliance costs
- Funding demand risk: NIH’s 15% indirect-cost cap could reduce research budgets available for product purchases
- Supply concentration risk: single-source antibodies face lead times of several months or more
- Liquidity risk: $60 million revolving facility matures July 1, 2029, with no outstanding borrowings at September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.